Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume

Shares of Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating) saw unusually-high trading volume on Monday . Approximately 54,657 shares changed hands during mid-day trading, a decline of 98% from the previous session’s volume of 2,638,332 shares.The stock last traded at $13.69 and had previously closed at $13.72.

Wall Street Analyst Weigh In

TAK has been the subject of a number of recent research reports. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 19th. Jefferies Financial Group downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Finally, Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $21.00 to $24.00 in a report on Tuesday, July 19th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $24.00.

Takeda Pharmaceutical Stock Performance

The stock’s fifty day moving average price is $14.09 and its two-hundred day moving average price is $14.30. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.75 and a current ratio of 1.18. The company has a market cap of $41.43 billion, a P/E ratio of 25.21, a P/E/G ratio of 0.56 and a beta of 0.70.

Takeda Pharmaceutical (NYSE:TAKGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 5.43% and a return on equity of 12.41%. The company had revenue of $7.51 billion during the quarter. As a group, equities analysts predict that Takeda Pharmaceutical Company Limited will post 2.25 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in TAK. First Republic Investment Management Inc. lifted its holdings in shares of Takeda Pharmaceutical by 17.1% during the 4th quarter. First Republic Investment Management Inc. now owns 35,142 shares of the company’s stock worth $479,000 after acquiring an additional 5,136 shares during the period. Dimensional Fund Advisors LP increased its position in Takeda Pharmaceutical by 37.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 117,449 shares of the company’s stock worth $1,601,000 after purchasing an additional 31,920 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Takeda Pharmaceutical by 534.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 273,002 shares of the company’s stock worth $3,721,000 after purchasing an additional 229,978 shares in the last quarter. Capital Fund Management S.A. acquired a new position in Takeda Pharmaceutical during the 4th quarter worth approximately $329,000. Finally, Qube Research & Technologies Ltd increased its position in Takeda Pharmaceutical by 3.8% during the 4th quarter. Qube Research & Technologies Ltd now owns 202,448 shares of the company’s stock worth $2,759,000 after purchasing an additional 7,368 shares in the last quarter. Institutional investors own 1.96% of the company’s stock.

Takeda Pharmaceutical Company Profile

(Get Rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.

Featured Stories

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.